WOWataru Okamoto

Wataru Okamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wataru Okamoto has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

    by Kazuaki Harada, Wataru Okamoto, Sachiyo Mimaki, Yasuyuki Kawamoto, Hideaki Bando, Riu Yamashita, Satoshi Yuki, Takayuki Yoshino, Yoshito Komatsu, Atsushi Ohtsu, et al.

    In the era of genome-guided personalized cancer treatment, we must understand chemotherapy-induced genomic changes in tumors. This study evaluated whether adjuvant FOLFOX chemotherapy modifies the mutational profile of recurrent colorectal cancer (CRC). Whole exome sequencing was performed on samples from primary CRC tumors, untreated metastatic tumors, and recurrent tumors following adjuvant FOLFOX chemotherapy. The samples were resected from four patients. The number of mutations or the mutation spectrum in individual patients was nearly identical. Copy number variants persisted regardless of FOLFOX therapy administration. The genomic signature of oxaliplatin exposure (G > T/C > A, T > A/A > T) was not enriched after FOLFOX chemotherapy. Overlapping single nucleotide variants (SNVs) and indels remained in 26–65% of the patient-matched tumor samples. One patient harbored an AKT1 E17K mutation in the recurrent tumor, whereas PIK3CA E542K and E88Q mutations were detected in the primary and untreated metastatic tumor samples. Genes related to intracellular Ca2+ homeostasis were enriched among the genes uniquely mutated after FOLFOX chemotherapy. We found that the mutation rates, mutation spectrum, and copy number variants were nearly identical regardless of the administration of FOLFOX therapy in the four CRC cases. The mutational discordance between the patient-matched tumor samples is likely caused by tumor heterogeneity and chemotherapy-induced clonal selection. These findings might be useful as pilot data for larger studies to clarify the changes in the mutational landscape induced by adjuvant FOLFOX chemotherapy.


  • A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer

    by Takeshi Kajiwara, Tomohiro Nishina, Hiroya Taniguchi, Kei Muro, Kiwamu Akagi, Hiroki Hara, Tadamichi Denda, Shuichi Hironaka, Toshihiro Kudo, Taroh Satoh, et al.

    Introduction: The detection of RAS (KRAS and NRAS) and BRAF gene mutations has been essential to determine the treatment strategy for metastatic colorectal cancer (CRC). A multiplex kit simultaneously detecting both gene mutations is required, although few genetic assays with high-quality assurance are established. We evaluated RAS/BRAF KIT (RASKET-B), a multiplex assay using PCR-reverse sequence specific oligonucleotide (PCR-rSSO) and xMAP® technology to concurrently detect 48 types of mutations in KRAS/NRAS codons 12, 13, 59, 61, 117 and 146 as well as the BRAF V600E mutation in a short turnaround time (4.5 h/96 specimens).

  • Open Access

    Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials

    by Yoshiaki Nagatani, Kohei Shitara, Hideaki Bando, Yasutoshi Kuboki, Wataru Okamoto, Takashi Kojima, Takayuki Yoshino, Toshirou Nishida, Atushi Ohtsu, Toshihiko Doi

    The prognosis of patients with gastrointestinal stromal tumor (GIST) after the failure of standard therapies is poor with supportive care alone. Guidelines recommend clinical trials, and patients with good performance status following standard therapies are often eligible for phase I clinical trials of investigational agents; however, there are no detailed reports on the clinical outcomes of GIST patients enrolled in these trials. We retrospectively reviewed the clinical outcomes of 21 consecutive GIST patients who were enrolled in one or more phase I clinical trials at a single center between March 2009 and November 2014. The median age was 57 years, and the median number of previous lines of standard chemotherapy was three. Chemotherapy before enrollment in a phase I clinical trial included imatinib, sunitinib, and regorafenib in 100, 95, and 43 % of patients, respectively. None of the patients achieved objective response. Ten patients (47.6 %) were determined to be stable according to the Response Evaluation Criteria in Solid Tumors; four of them (19.0 %) maintained their status for more than 24 weeks. Four patients achieved partial response according to the Choi criteria. No dose-limiting toxicity was observed; however, severe adverse events and grade 3 or higher toxicities were reported in one (4.8 %) and two patients (9.5 %), respectively. Although no treatment-related deaths occurred, one patient (4.8 %) died within 30 days after the last drug administration because of disease progression. The median progression-free survival was 1.9 months, and the median overall survival time has not been reached. Data suggested that phase I clinical trials were feasible and may provide prognostic benefits to GIST patients after standard therapies, indicating that enrollment in these studies may provide a treatment option for these patients.


  • The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer.

    by Atsuo Takashima, Wataru Okamoto, Shuichi Hironaka, Takeshi Kato, Yoshito Komatsu, Takeshi Kajiwara, Naoki Izawa, Taito Esaki, Hiroki Hara, Ryota Nakanishi, et al.

    4058 Background: We conduct the nationwide cancer genome screening project in Japan since 2015 using Next Generation Sequencing in advanced non-colorectal gastrointestinal (GI) cancer (aNon-CRC), called as SCRUM-Japan GI-SCREEN 2015-01-Non CRC. The objective is to evaluate the frequency of cancer genome alterations in aNon-CRC and to identify patients (pts) who are candidate for clinical trial for corresponding targeting agents. Methods: Pts with aNon-CRC including esophageal cancer (EC), gastric cancer (GC), and other types of aNon-CRC. Twenty ng of DNA and 10 ng of RNA were extracted from FFPE tumor samples and were analyzed by the Oncomine Cancer Research Panel (OCP) which allows to detect gene mutation, copy number variant (CNV) and fusions across 143 genes in a CLIA certified CAP accredited laboratory. The detected genomic variant data were classified according to whether genetic driver of cancer including gain- and loss-of-function or single nucleotide variant based on the Oncomine Knowledgebase. Results: As of October 31st in 2015, a total of 243 GC and 85 EC pts were enrolled and 235 GC and 83 EC samples were available. A total of 231 GC and 79 EC samples were analyzed and four GC and EC samples each are currently under analysis. The sequence with the OCP was successfully performed in 174 GC (75.3%) and 52 EC (65.8%). The most frequently detected mutations were TP53 (48.3%), PIK3CA (6.9%), KRAS, and SMAD4 (5.7%) in GC and were TP53 (76.9%), NFE2L2 (25.0%), CDKN2A, and PIK3CA (9.6%) in EC. Those of CNVs were ERBB2 (8.6%), CCNE1 (5.2%), FGFR2, and KRAS (4.0%) in GC and were CCND1 (44.2%), EGFR (13.5%), and SOX2 (9.6%) in EC. WIPF2-ERBB2 fusion and EGFR vIII were detected in GC and FGFR3-TACC3 fusion was detected in EC. Pts with PIK3CA or AKT1 mutation, MET or FGFR2 amplification and FGFR3-TACC3 fusion were enrolled in early clinical trials. Conclusions: This nationwide screening system is efficient to detect rare mutations in GI cancer. This novel knowledge provides an intriguing background to investigate new target approaches and represents a progress toward more precision medicine. Clinical trial information: UMIN000016344.

  • A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.

    by Yasutoshi Kuboki, Tomohiro Nishina, Kensei Yamaguchi, Eiji Shinozaki, Yoshito Komatsu, Satoshi Yuki, Kentaro Yamazaki, Hiroki Hara, Miki Fukutani, Yasue Uchida, et al.

    TPS3632 Background: In a RECOURSE phase III study, TAS-102 significantly improved progression-free survival (PFS) and overall survival (OS) over placebo in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies. We reported the combination of TAS-102 with bevacizumab (C-TASK FORCE trial) showed promising anti-tumor activities with mild toxicities (Kuboki Y, et al. ASCO 2015). Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptors (1,2,3), platelet-derived growth factor receptors (a, β), and fibroblast growth factor receptors (1,2,3). A global phase III study, called as the LUME-Colon 1, comparing nintedanib monotherapy versus placebo in pts with mCRC refractory to standard therapies is ongoing, on the basis of promising anti-tumor activities with mild toxicities in a phase I clinical study of nintedanib monotherapy (Mross et al.). Therefore, we initiated phase I/II study to assess efficacy and safety for the combination of TAS-102 with nintedanib. Methods: The key eligibility criteria were pts with mCRC refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-angiogenesis inhibitor and anti-EGFR antibody (if wild-type RAS) and without prior regorafenib and TAS-102; at least one measurable lesion; and ECOG performance status of 0 or 1. Phase I part was designed to determine the recommended phase II dose (RP2D) in a “3+3” cohort-based dose escalation design of nintedanib (150mg BID every day on level 1 and 200mg BID every day on level 2) with a fixed dose of TAS-102 (35 mg/m2 BID on days 1–5 and 8–12 q4w). Primary endpoint of the phase II part was an investigator-assessed PFS rate at 16 weeks in pts receiving the combination with RP2D. Using a single stage binomial design, this study required 52 pts, with an investigator-assessed PFS rate at 16 weeks of 40% deemed promising and 25% unacceptable (one-sided alpha = 0.1; beta = 0.2). Secondary endpoints included OS, PFS, objective response rate, disease control rate, safety, and pharmacokinetic parameters. The enrollment to phase II part began in January 2016. Clinical trial information: UMIN000017114. Clinical trial information: 000017114.


  • The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.

    by Takeshi Kato, Wataru Okamoto, Tetsuya Hamaguchi, Hiroki Hara, Hiroya Taniguchi, Takuro Mizukami, Tadamichi Denda, Toshikazu Moriwaki, Taito Esaki, Satoshi Yuki, et al.

    3591 Background: We conduct the nationwide cancer genome screening project in Japan from February 2014. Since February 2015, we introduced Next Generation Sequencing method to detect cancer genome alterations in advanced colorectal cancer (aCRC), called as SCRUM-Japan GI-SCREEN 2013-01-CRC. The objective is to evaluate the frequency of cancer genome alterations in aCRC and to identify patients who are candidate for clinical trial for corresponding targeting agents. Methods: This study is ongoing with the participation of 20 major cancer centers. Patients with aCRC who plan to or receive systemic chemotherapy were eligible. Twenty ng of DNA and 10 ng of RNA were extracted from formalin-fixed paraffin embedded (FFPE) tumor samples and were analyzed by the Oncomine Cancer Research Panel (OCP) which allows to detect gene mutation, copy number variant (CNV) and fusions across 143 genes in a CLIA certified CAP accredited laboratory. The detected genomic variant data were classified according to whether genetic driver of cancer, including gain- and loss-of-function or single nucleotide variant based on the Oncomine Knowledgebase. Results: As of October 31st in 2015, a total of 393 aCRC patients were enrolled and 360 samples were available. Out of 360 samples, 345 samples were analyzed and 15 samples are currently under analysis. The sequence with the OCP was successfully performed in 257 tumors (74.5%). The most frequently detected mutations were TP53 (66.9%), APC (56.4%), KRAS (38.9%), PIK3CA (12.1%), and BRAF (10.9%), and CNVs were ERBB2 (3.5%), FLT3 (2.3%), MYC (1.9%), and FGFR1 (1.6%). No gene fusion was detected so far. Patients with BRAF, PIK3CA or FGFR1 mutation were enrolled in early clinical trials. We plan to conduct the investigator initiated studies targeting aCRC patients with ERBB2 amplification and those with BRAF non-V600E mutations. Conclusions: This nationwide screening system is efficient to detect rare mutations in aCRC. This novel knowledge provides an intriguing background to investigate new target approaches in these patients and represents a progress toward more precision medicine. Clinical trial information: UMIN000016343.


  • A multiplexed NGS solution to evaluate potential tumor immune response and objectively stratify tumors by histopathology from FFPE samples.

    by Ann Mongan, Sophie Rozenzhak, Geoff Bien, Takayuki Yoshino, Wataru Okamoto, Hiroyoshi Nishikawa, Warren Tom, Jianping Zheng, Tim Looney, Fiona Hyland

    E14566 Background: The emergent T cell checkpoint therapy has offered durable and potential curative results for many NSCLC and melanoma patients. Nevertheless, fewer than half of subjects in trials exhibited positive response (Sharma, 2015). These results greatly illustrate the necessity for a better understanding of tumor microenvironment, tumor-lymphocyte interactions, and biomarkers that could predict drug sensitivity. In particular, PD-L1 expression has been reported to be a promising marker of response for PD-L1 therapies. However, standard methods for assessing PD-L1 protein level via immunohistochemistry have been shown to be inefficient and highly variable (McLaughlin, 2015) depending on selected antibodies, staining techniques, and site of tumors (Meng, 2015). Furthermore, as investigators are often also interested in measurements of additional biomarkers such as IFNg as well as markers of immune response, a gene panel approach offers a convenient solution to objectively quantify expression levels of these informative markers. Methods: Here we describe the identification and characterization of a research panel of approximately 200 genes designed to evaluate the expression of immune checkpoint pathway, level of tumor infiltrating lymphocytes, T cell regulation, interferon signaling, and presence of various lymphocyte subsets. Results: Our preliminary data shows that expression of the selected genes can stratify non-small cell lung cancer FFPE samples by histopathology (adenocarcinoma vs. squamous cell carcinoma). Furthermore, quantitative read out of the IFNg is clear and unambiguous for IFNg positive and negative controls. Gene expression was measured by NGS. Technical replicates were found to have > 0.99 correlation among each other. Assays on this research panel* were also found to be robust with respect to low input amount (1-10 ng RNA). Conclusions: We found a gene panel approach is a suitable tool to evaluate the expression of immune checkpoint pathway and level of tumor infiltrating lymphocytes, thereby offering insights into drug sensitivity *For Research Use Only. Not for use in diagnostic procedures.

  • Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.

    by Akihito Kawazoe, Kohei Shitara, Masaaki Noguchi, Shota Fukuoka, Yasutoshi Kuboki, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, et al.

    629 Background: Recently, anti-programmed death 1 (PD-1) antibody has shown promising efficacy in a phase II trial for patients with microsatellite instability-high (MSI-H) tumors, especially in those with metastatic colorectal cancer (mCRC). Currently, several clinical trials of anti-PD-1 antibody for patients with MSI-H mCRC are ongoing. However, little is known about the frequencies and clinicopathological features of MSI-H mCRC in Japanese patients. Methods: Patients with histologically confirmed adenocarcinoma of mCRC were eligible for this observational study. MSI status was analyzed in tumors using the MSI Analysis System (Promega) composed of 5 mononucleotide markers. KRAS, NRAS, BRAF and PIK3CA mutations were also evaluated using the multiplex kit. Results: A total of 232 patients were enrolled until August 31, 2015, of which MSI-H was detected in 5 patients (2.1%). Among five patients with MSI-H mCRC, median age was 45 years (28-75), four had tumors on right-sided colon, five had moderately differentiated adenocarcinoma, one had poorly differentiated adenocarcinoma, and three had stage IV disease at presentation. Overall survival for patients with MSI-H mCRC from the start of first-line systemic chemotherapy ranged from 8.1 to 62.0 month. All five patients with MSI-H mCRC had RAS wild-type tumors and two had BRAF V600E mutation. One patient with MSI-H mCRC was enrolled in a phase II trial of anti-PD-1 antibody. Conclusions: MSI-H mCRC is rare in Japanese patients. A large scale nationwide cancer genome screening project together with MSI status is required to evaluate more detailed clinicopathological features and facilitate the enrollment of patients with MSI-H mCRC for clinical trials with anti-PD-1 antibody.

  • Clinical outcomes in 21 patients with gastrointestinal stromal tumor(GIST)treated in phase I trials: the NCCHE Experience

    by Yoshiaki Nagatani, Kohei Shitara, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Takayuki Yoshino, Toshirou Nishida, Toshihiko Doi

  • Open Access

    A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

    by Akihito Kawazoe, Kohei Shitara, Shota Fukuoka, Yasutoshi Kuboki, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Nozomu Fuse, Takeharu Yamanaka, Toshihiko Doi, et al.

    The mutation in KRAS exon 2 is a validated biomarker of resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Several reports have confirmed associations of other RAS mutations with resistance to anti-EGFR therapy. However, the impact of BRAF and PIK3CA mutations on the efficacy of anti-EGFR therapy remains controversial. Little is known about the frequencies and clinicopathological features of these mutations, as well as the therapeutic effects of anti-EGFR therapy in mCRC patients with these mutations, especially in the Asian population. In this retrospective observational study, frequencies and clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations were evaluated in patients with mCRC. Among patients treated with anti-EGFR therapy, objective response, progression-free survival (PFS), and overall survival (OS) were evaluated according to gene status. Among 264 patients, mutations in KRAS exon 2, KRAS exons 3 or 4, NRAS, BRAF and PIK3CA were detected in 34.1%, 3.8%, 4.2%, 5.4% and 6.4%, respectively. Thus, a total of 12.1% of patients without KRAS exon 2 mutations had other RAS mutations. Primary rectal tumors tended to be more frequently observed in RAS mutant tumors. BRAF mutations were more frequently observed with right-sided colon, poorly differentiated or mucinous adenocarcinoma, and peritoneal metastasis. Among the 66 patients with KRAS exon 2 wild-type tumors treated with anti-EGFR agents, PFS (5.8 vs. 2.2 months) and OS (17.7 vs. 5.2 months) were significantly better in patients with all wild-type tumors (n = 56) than in those with any of the mutations (n = 10). The response rate also tended to be better with all wild-type tumors (26.8 vs. 0%). Other RAS and BRAF mutations were observed in KRAS exon 2 wild-type tumors, which were associated with some clinicopathological features and resistance to anti-EGFR therapy in our patient cohort.